Market Overview

Amyris Launches Safe Alternative To Talc-Based Baby Powder

Share:

EMERYVILLE, Calif., May 21, 2020 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced the launch of "Baby Cream to Powder" under its Pipette™ baby brand giving caring parents more choice and keeping babies safe.

This safe, talc-free alternative to baby powder goes on as an easy-to-apply cream to prevent and treat diaper rash and irritation and transforms into a silky powder on skin, eliminating the risk of powder inhalation. The announcement by Amyris comes on the heels of news that the largest and leading provider of baby care products will stop selling talcum-based baby powder in the U.S. and Canada amidst questions about its product safety.

The Pipette brand is quickly delivering to market innovative and effective products that are free of harmful ingredients. "Our Baby Cream to Powder addresses parents' concerns by eliminating dust, mess and irritation commonly associated with traditional powders," said Caroline Hadfield, President of Pipette.  "Our goal is to deliver innovative, best performing and safest, non-toxic alternative sustainable products that will help parents, babies, and families."

As with all Pipette products, 100% sugarcane-derived squalane is a main ingredient in Baby Cream to Powder, offering weightless hydration for baby's sensitive skin and antioxidant-rich mango seed butter helps restore the skin's natural balance. The creamy format makes it easy to apply in those hard to reach baby rolls or along the diaper line.

Pipette's Baby Cream to Powder is EWG (Environmental Working Group) Verified, Leaping Bunny Approved, dermatologist tested, pediatrician approved, hypoallergenic, nontoxic, vegan, and synthetic fragrance-free.

"Our Pipette and clean skincare consumer brands are experiencing very strong growth," said John Melo, President and Chief Executive Officer. "Based on current demand, we believe the consumer business has the potential to reach over $90 million in revenue for 2020. Consumers are focusing on healthy skin for themselves and their family and have moved their purchasing online. Sugarcane derived squalane is now clinically proven to provide significant nourishment for the skin microbiome, and we are very pleased to meet a critical need for the consumer at a time when the skin needs it most."

About Pipette
Pipette is a clean baby care brand with a mission to give every family the best start. We serve parents who strive to raise more conscious individuals while leaving behind a better planet for their children. With the same passion that led our scientists to ban over 2,000 potentially harmful ingredients from our labs and products, we've made protecting babies our goal by only using the safest, most necessary ingredients from the purest sources. With the most stringent standards of testing and safety, we create the highest quality clean formulations with sustainable packaging. Because we believe that when we make it easy for parents to take care of their little ones, we are taking care of our future and our planet. Pipettebaby.com

About Amyris
Amyris (NASDAQ:AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world's top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands - all built around its No Compromise® promise of clean ingredients: Biossance™ clean beauty skincare, Pipette™ clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com.

Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as expected Pipette sales performance and potential new product launches and anticipated Amyris product revenue and product revenue growth from its consumer business. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, risks related to potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo, No Compromise, Biossance, Pipette, and Purecane are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/amyris-launches-safe-alternative-to-talc-based-baby-powder-301063624.html

SOURCE Amyris, Inc.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com